Lantern Pharma Inc. is a clinical-stage biotechnology company specializing in oncology drug discovery and development through artificial intelligence, machine learning, and genomics. At its core is the proprietary RADR platform, which analyzes hundreds of billions of oncology-focused data points and over 200 advanced machine learning algorithms to identify biomarkers, predict drug responses, design clinical trials, and accelerate the development of precision cancer therapies for solid tumors and blood cancers. The company's pipeline features lead candidates such as LP-300 in phase 2 trials for non-small cell lung cancer in never-smokers, LP-184 in phase 1 for solid tumors including pancreatic, breast, bladder, lung, glioblastoma, and other CNS cancers, and LP-284 in phase 1 for non-Hodgkin’s lymphomas like mantle cell and double hit lymphoma, alongside an ADC program spanning 12 cancer indications. Lantern Pharma Inc. focuses on stratifying patients into responders and non-responders to de-risk trials, develop companion diagnostics, and target genetically defined subsets with high unmet needs. Founded in 2013 and headquartered in Dallas, Texas, it operates at the intersection of AI and precision oncology to transform drug development processes.